The deal between the White House and Democrats would raise the debt ceiling for two years and permanently end the sequester.Politicsread more
"Whether it's this year or next year, the odds of another economic downturn are high — and growing," Warren says.Politicsread more
A group of gold miners stocks, "BAANG," are better plays than mega-cap FAANG names, according to John Roque, technical analyst at Wolfe Research.Marketsread more
A different oil pricing dynamic has been evolving with new supply calculations based on the U.S. as the world's largest producer.Market Insiderread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
Trade tensions that could lead to layoffs and a pullback from consumers are at the center of the recession case.Economyread more
Microsoft and OpenAI announced a new partnership to build artificial general intelligence to tackle more complex tasks than current AI.Technologyread more
There's a reason the film industry doesn't measure the success of modern movies against those of the past — movie ticket inflation isn't an exact science.Entertainmentread more
A US judge presiding over multidistrict litigation alleging J&J's talc baby powder causes ovarian cancer starts hearing from experts Monday.Health and Scienceread more
Investors with $1 million or more in the market expect the pace of stock market gains to slow over the remainder of 2019. But these wealthy self-directed brokerage account...Investingread more
Air-conditioner maker Lennox International pointed to colder weather as a key reason for cutting guidance and underperforming in the second quarter.Marketsread more
Booming demand for steady, dividend-paying stocks is fully priced into shares of Merck, said BMO Capital Markets, which downgraded its rating to market perform from outperform. Plus, political risks could weigh on big drug stocks in the run-up to the November presidential election, the firm said.
"There is clearly a strong market demand for diversified, steady growing stocks that pay a relatively attractive dividend," said BMO Capital's Alex Arfaei in a Monday note to clients. "We believe this has been a key driver behind the strong performance for some of the stocks in our major pharma coverage universe, and as a result these stocks now have valuations that are close to our price targets"
Dipping government bond yields and and plateauing interest rates have made major pharmaceutical stocks like Abbvie, Pfizer and Merck look attractive to investors, the analyst said. But that theme has likely played out, he said.